Annals of Emergency Medicine
Volume 45, Issue 6 , Pages 614-619 , June 2005

Resuscitative Effect of a γ-Aminobutyric Acid B Receptor Antagonist on γ-Hydroxybutyric Acid Mortality in Mice

  • Mauro A.M. Carai, PharmD

      Affiliations

    • Corresponding Author InformationAddress for reprints: Mauro A. M. Carai, PharmD, Bernard B. Brodie Department of Neuroscience, University of Cagliari, Viale A. Diaz 182, I-09126 Cagliari, Italy; 39-070-302227, fax 39-070-302076
    • ,
  • Giancarlo Colombo, PhD
    • ,
  • Gian Luigi Gessa, MD

Received 18 September 2004 ,Revised 7 December 2004 ,Accepted 15 December 2004.

References 

  1. Wong CGT, Gibson KM, Snead OC. From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci. 2004;25:29–34
  2. Zvosec DL, Smith SW, McCutcheon JR, et al. Adverse events including death, associated with the use of 1,4-butanediol. N Engl J Med. 2001;344:87–94
  3. Mason P, Kerns WP. Gamma hydroxybutyric acid (GHB) intoxication. Acad Emerg Med. 2002;9:730–739
  4. Shannon M, Quang LS. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care. 2000;16:435–440
  5. Nissbrandt H, Engberg G. The GABAB-receptor antagonist, CGP 35348, antagonizes γ-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice. J Neural Transm. 1996;103:1255–1263
  6. Carai MAM, Colombo G, Brunetti G, et al. Role of GABAB receptors in the sedative/hypnotic effect of γ-hydroxybutyric acid. Eur J Pharmacol. 2001;428:315–321
  7. Quang LS, Desai MC, Kraner JC, et al. Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxybutyric acid precursor 1,4-butanediol in CD-1 mice. Ann NY Acad Sci. 2002;965:461–472
  8. Mathivet R, Bernasconi J, De Barry C, et al. Binding characteristics of the gamma-hydroxybutyric acid as a weak but selective GABAB receptor antagonist. Eur J Pharmacol. 1997;321:67–75
  9. Lingenhoehl K, Brom R, Heid J, et al. γ-Hydroxybutyrate is a weak agonist at recombinant GABAB receptors. Neuropharmacology. 1999;38:1667–1673
  10. Hechler V, Ratomponirina C, Maitre M. γ-Hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide. J Pharmacol Exp Ther. 1997;281:753–760
  11. Gobaille S, Hechler V, Andriamampandry C, et al. γ-Hydroxybutyrate modulates synthesis and extracellular concentration of gamma-aminobutyric acid in discrete rat brain regions in vivo. J Pharmacol Exp Ther. 1999;290:303–309
  12. Barbaccia ML, Colombo G, Affricano D, et al. GABAB receptor-mediated increase of neurosteroids by γ-hydroxybutyric acid. Neuropharmacology. 2002;42:782–791
  13. Schmidt-Mutter C, Pain L, Sandner G, et al. The anxiolytic effect of γ-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, flumazenil. Eur J Pharmacol. 1998;342:21–27
  14. Andriamampandry C, Taleb O, Viry S, et al. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. 2003;17:1691–1693
  15. Martellotta MC, Cossu G, Fattore L, et al. Intravenous self-administration of gamma-hydroxybutyric acid in drug-naive mice. Eur Neuropsychopharmacol. 1998;8:293–296
  16. Hechler V, Gobaille S, Bourguignon J-J, et al. Extracellular events induced by γ-hydroxybutyrate in striatum: a midrodialysis study. J Neurosci. 1991;56:938–944
  17. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of γ-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett. 2004;224:71–74
  18. Gupta M, Greven R, Jansen EE, et al. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (gamma-hydroxybutyric aciduria). J Pharmacol Exp Ther. 2002;302:180–187
  19. Liljequist S, Engel J. Effects of GABAergic agonists and antagonists on various ethanol-induced behavioral changes. Psychopharmacology. 1982;78:71–75
  20. Bilsky EJ, Marglin SH, Reid LD. Using antagonists to assess neurochemical coding of a drug's ability to establish a conditioned place preference. Pharmacol Biochem Behav. 1990;37:425–431
  21. Cook CD, Aceto MD, Coop A, et al. Effects of the putative antagonist NCS382 on the behavioral pharmacological actions of gamma-hydroxybutyrate in mice. Psychopharmacology. 2002;160:99–106
  22. Bernasconi R, Mathivet P, Otten U, et al. Part of the pharmacological actions of γ-hydroxybutyrate are mediated by GABAB receptors. In:  Tunnicliff G,  Cash CD editor. Gamma-hydroxybutyrate: Molecular, Functional and Clinical Aspects. London, England: Taylor and Francis; 2002;p. 28–63

 Author contributions: MAMC conceived the study, designed and conducted the experiments, analyzed the data, and drafted the manuscript. GC contributed to the conducting of the experiments and manuscript revision. GLG obtained research funding, supervised the conduct of the study, and contributed to manuscript revision. MAMC takes responsibility for the paper as a whole.Funding and support: The present study was partially supported by a grant from the Italian Ministry for Education and Research to the “Center of Excellence on Neurobiology of Dependence,” Department of Neuroscience, University of Cagliari.

PII: S0196-0644(04)01810-4

doi: 10.1016/j.annemergmed.2004.12.013

Annals of Emergency Medicine
Volume 45, Issue 6 , Pages 614-619 , June 2005

Article Tools

* Image Usage & Resolution